1,870 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by Harbour Capital Advisors LLC

Harbour Capital Advisors LLC acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, Holdings Channel.com reports. The fund acquired 1,870 shares of the medical research company’s stock, valued at approximately $313,000.

Other hedge funds have also recently modified their holdings of the company. Oppenheimer Asset Management Inc. lifted its position in Natera by 14.8% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 20,197 shares of the medical research company’s stock valued at $2,187,000 after acquiring an additional 2,611 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Natera by 1.2% during the second quarter. Envestnet Asset Management Inc. now owns 187,438 shares of the medical research company’s stock valued at $20,298,000 after purchasing an additional 2,148 shares during the last quarter. Capital Wealth Planning LLC purchased a new stake in shares of Natera in the 2nd quarter worth approximately $250,000. Massachusetts Financial Services Co. MA increased its position in Natera by 6.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock valued at $259,634,000 after buying an additional 148,917 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Natera by 35.6% during the second quarter. Dimensional Fund Advisors LP now owns 264,801 shares of the medical research company’s stock valued at $28,680,000 after buying an additional 69,523 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 1,196 shares of the business’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the completion of the transaction, the insider now directly owns 110,695 shares in the company, valued at $13,085,255.95. The trade was a 1.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Fesko sold 669 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $159.60, for a total value of $106,772.40. Following the sale, the insider now directly owns 114,142 shares in the company, valued at $18,217,063.20. This represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 123,409 shares of company stock valued at $20,045,631 in the last 90 days. Company insiders own 7.60% of the company’s stock.

Natera Trading Down 3.3 %

Shares of NTRA opened at $169.30 on Tuesday. Natera, Inc. has a fifty-two week low of $59.80 and a fifty-two week high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company’s fifty day moving average is $160.14 and its 200 day moving average is $132.44. The stock has a market capitalization of $22.35 billion, a PE ratio of -96.19 and a beta of 1.65.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.95) EPS. Sell-side analysts expect that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on NTRA. JPMorgan Chase & Co. raised their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Canaccord Genuity Group upped their target price on shares of Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. The Goldman Sachs Group boosted their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. TD Cowen increased their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Morgan Stanley boosted their price target on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $158.00.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.